
## **Charlotte Ariyan**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7572741/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mitochondrial Dysfunction in the Elderly: Possible Role in Insulin Resistance. Science, 2003, 300, 1140-1142.	12.6	1,848
2	Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. Journal of Clinical Investigation, 2002, 109, 1345-1350.	8.2	552
3	Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nature Medicine, 2011, 17, 1094-1100.	30.7	476
4	Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. Journal of Clinical Investigation, 2002, 109, 1345-1350.	8.2	373
5	Transcriptional Basis of Mouse and Human Dendritic Cell Heterogeneity. Cell, 2019, 179, 846-863.e24.	28.9	359
6	Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 399-413.	1.6	190
7	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	10.7	155
8	Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. Oncologist, 2016, 21, 848-854.	3.7	154
9	Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. Annals of Surgical Oncology, 2018, 25, 356-377.	1.5	130
10	Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab. JAMA Oncology, 2020, 6, 402.	7.1	125
11	Prognosis of Acral Melanoma: A Series of 281 Patients. Annals of Surgical Oncology, 2013, 20, 3618-3625.	1.5	123
12	CTLA-4 up-regulation plays a role in tolerance mediated by CD45. Nature Immunology, 2001, 2, 58-63.	14.5	113
13	Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer Immunology Research, 2018, 6, 189-200.	3.4	102
14	Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor. Cancer Immunology Research, 2014, 2, 70-79.	3.4	100
15	Targeting Signal 1 Through CD45RB Synergizes with CD40 Ligand Blockade and Promotes Long Term Engraftment and Tolerance in Stringent Transplant Models. Journal of Immunology, 2001, 166, 322-329.	0.8	90
16	Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment. EBioMedicine, 2017, 18, 56-61.	6.1	83
17	Assessment and management of patients with abnormal calcium. Critical Care Medicine, 2004, 32, S146-S154.	0.9	82
18	Outcome of Patients with a Positive Sentinel Lymph Node who do not Undergo Completion Lymphadenectomy. Annals of Surgical Oncology, 2010, 17, 514-520.	1.5	74

CHARLOTTE ARIYAN

#	Article	IF	CITATIONS
19	Primary and Metastatic Melanoma With NTRK Fusions. American Journal of Surgical Pathology, 2018, 42, 1052-1058.	3.7	72
20	Cutting Edge: Transplantation Tolerance through Enhanced CTLA-4 Expression. Journal of Immunology, 2003, 171, 5673-5677.	0.8	71
21	Observation After a Positive Sentinel Lymph Node Biopsy in Patients with Melanoma. Annals of Surgical Oncology, 2014, 21, 3117-3123.	1.5	63
22	Positive Nonsentinel Node Status Predicts Mortality in Patients with Cutaneous Melanoma. Annals of Surgical Oncology, 2009, 16, 186-90.	1.5	61
23	Immunological Insights from Patients Undergoing Surgery on Ipilimumab for Metastatic Melanoma. Annals of Surgical Oncology, 2013, 20, 3106-3111.	1.5	47
24	Locoregional Lymphadenectomy in the Surgical Management of Anorectal Melanoma. Annals of Surgical Oncology, 2013, 20, 2339-2344.	1.5	45
25	Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients. Annals of Surgical Oncology, 2017, 24, 939-946.	1.5	41
26	Safety and Feasibility of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma (SAFE-MILND). Annals of Surgery, 2017, 265, 192-196.	4.2	39
27	Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available Biomarker Associated with Death due to Disease in High Risk Nonmetastatic Melanoma. Annals of Surgical Oncology, 2017, 24, 1989-1996.	1.5	39
28	Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. Annals of Surgical Oncology, 2020, 27, 1180-1188.	1.5	39
29	The Current Status of Laparoscopic Adrenalectomy. Advances in Surgery, 2007, 41, 133-153.	1.3	36
30	Reliability of identification of 655 sentinel lymph nodes in 263 consecutive patients with malignant melanoma 1 1No competing interests declared Journal of the American College of Surgeons, 2004, 198, 924-932.	0.5	33
31	Inhibition of apoptosis by survivin improves transplantation of pancreatic islets for treatment of diabetes in mice. EMBO Reports, 2006, 7, 438-443.	4.5	31
32	Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion. Journal of Surgical Oncology, 2014, 109, 405-409.	1.7	23
33	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Annals of Surgical Oncology, 2022, 29, 3694-3708.	1.5	21
34	Factors Associated With Inconsistent Sun Protection in First-Degree Relatives of Melanoma Survivors. Qualitative Health Research, 2012, 22, 934-945.	2.1	18
35	Laparoscopic skill assessment of practicing surgeons prior to enrollment in a surgical trial of a new laparoscopic procedure. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 3313-3319.	2.4	17
36	Transected thin melanoma: Implications for sentinel lymph node staging. Journal of Surgical Oncology, 2018, 117, 567-571.	1.7	15

CHARLOTTE ARIYAN

#	Article	IF	CITATIONS
37	International Multi-institutional Management and Outcome of Melanoma Patients with Positive Sentinel Lymph Nodes in More than One Nodal Basin. Annals of Surgical Oncology, 2014, 21, 4324-4329.	1.5	13
38	Surgical perspectives in gastrointestinal disease: A study of quality of life outcomes in esophageal, pancreatic, colon, and rectal cancers. World Journal of Gastroenterology, 2006, 12, 3213.	3.3	12
39	History of regional chemotherapy for cancer of the extremities. International Journal of Hyperthermia, 2008, 24, 185-192.	2.5	11
40	Predicting the development of brain metastases in patients with local/regional melanoma. Journal of Surgical Oncology, 2014, 109, 770-774.	1.7	11
41	Update on Immunotherapy in Melanoma. Surgical Oncology Clinics of North America, 2015, 24, 337-346.	1.5	11
42	Association of HPV42 with digital papillary adenocarcinoma and the use of in situ hybridization for its distinction from acral hidradenoma and diagnosis at non-acral sites. Modern Pathology, 2022, 35, 1405-1410.	5.5	11
43	Prognostic significance of drainage to pelvic nodes at sentinel lymph node mapping in patients with extremity melanoma. Melanoma Research, 2013, 23, 40-46.	1.2	10
44	Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation. Oncotarget, 2017, 8, 105000-105010.	1.8	10
45	Editorial on "Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysisâ€: Annals of Surgical Oncology, 2007, 14, 3295-3296.	1.5	6
46	Desmoplastic Melanoma in African American Patients. Archives of Dermatology, 2010, 146, 796-7.	1.4	4
47	Randomized Clinical Trials in Melanoma. Surgical Oncology Clinics of North America, 2010, 19, 13-31.	1.5	4
48	CD30â€positive lymphoproliferative disorders arising after regional therapy for recurrent melanoma: A report of two cases and analysis of CD30 expression. Journal of Surgical Oncology, 2014, 110, 258-264.	1.7	4
49	Complete lymph node dissection in melanoma. Lancet Oncology, The, 2016, 17, 688-689.	10.7	3
50	Comment on "Comparison of surgical margins for lentigo maligna versus melanoma in situ― Journal of the American Academy of Dermatology, 2019, 81, e115-e116.	1.2	3
51	SURGICAL MANAGEMENT OF SOFT TISSUE SARCOMA: HISTOLOGIC TYPE AND GRADE GUIDE SURGICAL PLANNING AND INTEGRATION OF MULTIMODALITY THERAPY. , 2010, , 1057-1069.		2
52	MelMART Trial: It's Now or Never. Annals of Surgical Oncology, 2018, 25, 2493-2495.	1.5	2
53	An Update on Randomized Clinical Trials in Melanoma. Surgical Oncology Clinics of North America, 2017, 26, 559-586.	1.5	1